LivaNova PLC (NASDAQ:LIVN) Stock Now Rated “Moderate Buy” by Wall Street Brokerages

LivaNova PLC (NASDAQ:LIVN) has earned a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokers that have issued a report on the stock in the last year is $87.75.

A number of analysts have issued reports on the company. Barclays raised LivaNova to a “strong-buy” rating in a research note on Wednesday, October 7th. Piper Sandler reissued an “overweight” rating and set a $90.00 price target (up from $87.00) on shares of LivaNova in a research report on Wednesday, September 2nd. Weiss Ratings raised shares of LivaNova from a “hold (c)” rating to a “hold (c+)” rating in a report on Tuesday, August 18th. Stifel Nicolaus set a $85.00 price objective on shares of LivaNova in a report on Wednesday, August 5th. Finally, Mizuho increased their price target on shares of LivaNova from $90.00 to $95.00 and gave the company an “outperform” rating in a research note on Wednesday, July 15th.

LivaNova Stock Up 3.2%

Shares of NASDAQ LIVN opened at $78.50 on Friday. The stock has a market cap of $4.32 billion, a PE ratio of 21.19 and a beta of 0.87. The company has a current ratio of 1.45, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. LivaNova has a 12-month low of $48.82 and a 12-month high of $85.76. The company has a 50-day moving average of $78.51 and a 200 day moving average of $75.50.

LivaNova (NASDAQ:LIVN) last released its earnings results on Thursday, August 6th. The company reported $1.26 earnings per share for the quarter, topping analysts’ consensus estimates of $1.09 by $0.17. The business had revenue of $390.59 million for the quarter, compared to analyst estimates of $380.50 million. LivaNova had a net margin of 12.82% and a return on equity of 16.35%. The business’s revenue was up 10.8% on a year-over-year basis. During the same period last year, the company posted $1.05 EPS. As a group, sell-side analysts predict that LivaNova will post 3.78 EPS for the current fiscal year.

Insider Activity at LivaNova

In related news, Director Francesco Bianchi sold 3,500 shares of the stock in a transaction that occurred on Thursday, September 10th. The stock was sold at an average price of $78.01, for a total value of $273,035.00. Following the completion of the transaction, the director directly owned 4,434 shares in the company, valued at approximately $345,896.34. This represents a 44.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Brooke Story sold 2,300 shares of the stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $81.42, for a total value of $187,266.00. Following the completion of the transaction, the director owned 7,488 shares of the company’s stock, valued at $609,672.96. The trade was a 23.50% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 7,450 shares of company stock worth $591,839. Corporate insiders own 0.35% of the company’s stock.

Institutional Investors Weigh In On LivaNova

A number of institutional investors and hedge funds have recently added to or reduced their stakes in LIVN. Allworth Financial LP grew its holdings in shares of LivaNova by 93.5% during the 2nd quarter. Allworth Financial LP now owns 298 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the period. Farther Finance Advisors LLC increased its position in shares of LivaNova by 59.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 452 shares of the company’s stock worth $35,000 after purchasing an additional 169 shares during the last quarter. Public Employees Retirement System of Ohio purchased a new stake in LivaNova in the 2nd quarter valued at about $37,000. Integrated Wealth Concepts LLC purchased a new stake in LivaNova in the 2nd quarter valued at about $119,000. Finally, EverSource Wealth Advisors LLC lifted its position in LivaNova by 103.6% in the first quarter. EverSource Wealth Advisors LLC now owns 1,623 shares of the company’s stock valued at $103,000 after buying an additional 826 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova PLC (NASDAQ: LIVN) is a medical device company that develops and markets technologies for the treatment of cardiovascular and neurological conditions. The company’s principal businesses are organized around its Cardiopulmonary and Neuromodulation segments.

Its cardiopulmonary portfolio includes heart-lung machines, oxygenators, perfusion systems and other equipment used during cardiopulmonary bypass procedures, as well as technologies designed to support cardiac surgery and related clinical applications.